Topic: Early-Phase Exposure-Response

Worked Analysis of a Phase I Biomarker Dataset

Using Biomarker Thresholds for Phase I Progression Decisions

Turnover Models for Delayed Biomarker Responses

Translating Biomarker Response Into Target Engagement Evidence

Reconciling Discordant Biomarkers in Phase I

Quantifying Uncertainty in Early-Phase Biomarker Effects

Modeling Repeated Biomarker Measures Within Participants

Mapping Phase I Decisions to Biomarker Estimands

Linking Biomarker Changes to Individual Drug Exposure

Interpreting Flat, Noisy, or Nonmonotonic Biomarker Responses